This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit April 09, 2014


 

Advertisement

Large-scale study reinforces value of screenings for colorectal cancer prevention
Chicago Tribune
Among cancers that affect both men and women, colorectal cancer is the second leading cause of cancer-related deaths in the United States, according to the Centers for Disease Control and Prevention (CDC). Deaths from colorectal cancer could be cut in half if people 50 years of age and older underwent routine colonoscopy screenings, said Sanath Kumar, MD, a colorectal surgeon on staff at Advocate South Suburban Hospital in Hazel Crest, Ill. A recent analysis of medical data from nearly 90,000 people strongly reinforces the importance of Dr. Kumar's recommendation.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Early relapse risk is higher when omitting radiotherapy in PET-negative early Hodgkin lymphoma
Oncology Nurse Advisor
The risk of early relapse is increased when radiotherapy is omitted in patients with stage I/II Hodgkin lymphoma whose PET scan findings are negative, according to an interim trial analysis. Both arms of this trial found that early outcomes were excellent; however, the trial's final analysis should reveal whether these initial findings are maintained over time. The main objective of this trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Version 3 of the CP³R now available
ACS
The latest version of the Cancer Program Practice Profile Reports (CP³R) has been posted with the following features:
  • Data are displayed for diagnosis years 2009, 2010, and 2011.
  • Three new breast measures have been added (see more information at http://www.facs.org/cancer/qualitymeasures.html).
  • Registrars can edit codes that affect whether or not the case belongs in the denominator of the measures, replacing the function of the former "censor" button.
  • Navigation is simplified, and both facility and comparison performance rates update when changes are made.
  • Documentation is improved (see http://www.facs.org/cancer/ncdb/cp3r.html).

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  The Top 10 Metrics to Maximize Your Practice's Revenue

MediGain has analyzed the top physicians offices around the country and compiled the Top 10 Metrics they use to maximize their practice's revenue. You can't manage what you can't measure. Here are 10 metrics that you can track so you can spend more time providing quality health care for your patients. Plus, you will end up with more cash at the end of the day/month/year.
 


p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for patients with rectal cancer
BMC Cancer
Since the report of CAO/ARO/AIO-94 trial showing an improved local recurrence rate and reduced toxicity with preoperative chemoradiotherapy (CRT), preoperative CRT has become the standard treatment option for clinical stage T3/4 or node-positive rectal cancer. However, many patients still suffer recurrence and death after preoperative CRT and surgery, especially those who do not respond to the preoperative CRT. The patients who achieved complete regression after preoperative CRT attained a five-year disease free survival (DFS) of 86 percent, whereas patients who showed low grade of regression showed a five-year DFS of not more than 63 percent, reappraising the need for a predictive marker of response to preoperative CRT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Register now for the 2014 CoC workshop — Strengthening Your Cancer Program...Enriching the Coordinators' Role
Commission on Cancer
On June 19-20 in Chicago, the Commission on Cancer (CoC) will hold a new workshop entitled Strengthening Your Cancer Program…Enriching the Coordinators' Role. This program provides information and case studies on the roles and responsibilities of the various CoC-designated coordinators. The two-day program will cover what the various coordinators' roles are, what their roles on the cancer committee involve, and how to meet and improve the required responsibilities based on the CoC Standards. Register for the program. Program fees are $650 if registration is received on or before May 15 and $750 if registration is received after May 15.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Study: Fertility drugs may not raise breast cancer risk
CBS News
Widely used fertility drugs don't seem to increase a woman's risk of breast cancer, according to a new study. Researchers analyzed data from more than 9,800 American women who were evaluated for infertility between 1965 and 1988 and followed until 2010. During the follow-up period, 749 of the women developed breast cancer. Overall, women who took Clomid (clomiphene citrate) or gonadotropins as part of fertility treatments were not more likely to develop breast cancer than those who didn't take the drugs, according to the study in the current issue of the journal Cancer Epidemiology, Biomarkers and Prevention.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Register now — Strengthening Your Cancer Program... Utilizing the Rapid Quality Reporting System to Comply with the New Commendation Standard
Commission on Cancer
Strengthening Your Cancer Program...Utilizing the Rapid Quality Reporting System to Comply with the New Commendation Standard will be held on June 18 in Chicago, the day before the 2014 CoC Workshop. This workshop will provide important information to help your program comply with the new commendation standard that requires programs, from initial enrollment and throughout the three-year accreditation period, to participate in the Rapid Quality Reporting System (RQRS). Register now for the program; registration fees are $250 if registration is received on or before May 15 and $300 if registration is received after May 15, 2014.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


High BMI, body fat percentage may increase risk for thyroid cancer
Endocrine Today
Body size measurements, particularly BMI and percentage of body fat, appear to significantly relate to an increased risk for papillary thyroid cancer, according to recent findings. In the pooled analysis, researchers analyzed data from three case-control studies conducted between 1999 and 2013 in the United States, Italy, and Germany. The combined studies comprised 1,917 patients with papillary thyroid cancer (PTC) and 2,127 control participants with no history of cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Differentiation of benign fluid collections from soft-tissue sarcomas on FDG-PET/CT
Journal of Cancer
Soft-tissue sarcomas (STSs) are mesenchymal-origin neoplasms characterized by locally aggressive behavior and a propensity for metastases. Intralesional heterogeneity, a well-documented phenomenon in STSs, can lead to imaging characteristics on US, CT, MRI, and 18F-fluorodeoxyglucose (FDG) PET that can be confused with those of benign fluid collections (BFs) such as hematomas, abscesses, and postoperative fluid collections. This overlap in imaging appearance leads to diagnostic dilemmas in two main clinical situations: at initial diagnosis of a soft-tissue mass and in differentiation of recurrent STS from a BF on postoperative imaging.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The Recovery Room Show — New episode available
ACS
You understand health, but do you understand medicine? Making sense of modern medicine, The Recovery Room, supported by the American College of Surgeons and hosted by Frederick L. Greene, MD, FACS, is an audio conversation with experts in surgery, medicine, ethics, and public health about the latest developments in medicine and health care. The latest episode, "Smoking Cessation and the Surgical Patient," is now available. It features Eric Skipper, MD, FACS, chief of adult cardiothoracic surgery at the Sanger Heart & Vascular Institute, Charlotte, N.C., and Michael Rosen, MD, FACS, professor of surgery and chief of GI and general surgery at Case Western Reserve University, Cleveland, Ohio.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Primary androgen deprivation ineffective for most early prostate cancer
Oncology Nurse Advisor
In a study of more than 15,000 men with early-stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment. The research team, led by scientists at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., said that the risks of serious adverse events associated with the treatment, which has been linked to impaired cognition, heart disease, diabetes, and other disorders, "mitigates against any clinical or policy rationale for use of primary androgen deprivation therapy in these men."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


National Accreditation Program for Breast Centers presents the Pursuing Excellence through Accreditation Workshop
NAPBC
Plan now to attend the Pursuing Excellence through Accreditation Workshop May 23 in Chicago. Designed for centers seeking accreditation for the first time as well as centers due for re-accreditation, this program will increase your understanding of the National Accreditation Program for Breast Centers (NAPBC) accreditation process and help you prepare for the survey visit. Space is limited, so please make sure you register early.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 
Advertisement

Advertisement



The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Samantha Emerson, Content Editor, 469.420.2669
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

April 2, 2014
March 26, 2014
March 19, 2014
March 19, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063